Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04160832 · ClinicalTrials.gov registry record

Prevalence and Spectrum of Cancer Susceptibility Among Patients with Advanced Colorectal Polyps

A clinical trial of Colorectal Neoplasm, sponsored by University of Colorado, Denver.

Completed
Registry status
200
Enrollment target
1
Study location

NCT04160832 is a study of Colorectal Neoplasm that has completed, run by University of Colorado, Denver. The registered enrollment target is 200 participants, roughly in line with the 219-participant average among 4 other Colorectal Neoplasm trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04160832, a study of Colorectal Neoplasm, has completed, sponsored by University of Colorado, Denver.

COMPLETED
Registry status
200 participants
Enrollment target
1
Study location

Study Summary

The study is being conducted to determine the prevalence and risk factors for germline cancer susceptibility genetic mutations among patients with advanced colorectal polyps.

Conditions Studied

Interventions

  • GENETIC Multi-Cancer Cancer Panel

Study Locations (1)

Colorado

  • University of Colorado Denver - Aurora

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2019-10-24
Est. Completion 2024-08-30

Sponsor

University of Colorado, Denver

1,283 total trials

What the Registry Record Tells You About NCT04160832

The ClinicalTrials.gov registry entry for NCT04160832 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 219-participant average among 4 other Colorectal Neoplasm trials with a reported enrollment target. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Colorectal Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Multi-Cancer Cancer Panel is the first listed.

NCT04160832 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT04160832 about?

NCT04160832 is a clinical study titled "Prevalence and Spectrum of Cancer Susceptibility Among Patients with Advanced Colorectal Polyps". The study is being conducted to determine the prevalence and risk factors for germline cancer susceptibility genetic mutations among patients with advanced colorectal polyps.

What is the current status of trial NCT04160832?

This trial is currently completed. The enrollment target is 200 participants. The study started on 2019-10-24. Estimated completion is 2024-08-30.

What conditions does trial NCT04160832 study?

This clinical trial studies the following conditions: Colorectal Neoplasm.

What interventions are being tested in trial NCT04160832?

The interventions under investigation include: Multi-Cancer Cancer Panel (GENETIC).

Who is sponsoring clinical trial NCT04160832?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04160832 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Colorectal Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.